Regulatory Insights

  1. Why Driving Impairment Evaluation Is Becoming More Important In CNS Drug Development 7/30/2026

    Vague warning labels leave patients and prescribers guessing about driving safety. Discover recent compliance data and learn how simulation studies clarify real-world functional risk.

  2. Building the Blueprint: What Psychedelic Trials Need Now 7/29/2026

    Discover how leading experts are addressing recent regulatory reviews to shape the next phase of psychedelic clinical research.

  3. What 9 Years Of MDR Experience Is Changing About PMCF Planning 7/28/2026

    Re-evaluate your compliance roadmap by exploring expert perspectives on navigating regulatory shifts, distinguishing core surveillance obligations, and building a defensible, value-driven clinical data strategy.

  4. The Fastest Route To Compliant Medical Device Trials 7/24/2026

    Watch a live build of compliant eCRFs and ePROs and see how lean teams can go from protocol to first patient faster without sacrificing regulatory readiness.

  5. UK Clinical Trial Regulations Reform 7/24/2026

    UK trial regulations have been overhauled. Learn what faster approval pathways, stricter publication rules, and longer retention requirements mean for your operations.

  6. ICH E6(R3) Annex 2: Navigating GCP Requirements For Decentralized Trials 7/24/2026

    Implementing decentralized components or real-world data requires proactive alignment with updated GCP standards for data access, remote consent, and multi-stream investigator oversight.

  7. The Evolution Of GLP-1s: Overcoming Clinical Development Challenges 7/23/2026

    Explore clinical development trends, recruitment hurdles, study design strategies, and emerging therapies shaping obesity and metabolic disease research.

  8. Five Preventable Clinical Design Pitfalls And How To Avoid Them 7/21/2026

    While late-stage trial attrition is often attributed to inadequate safety or efficacy, the true failure may be insufficient upstream planning and/or misalignment between clinical and commercial goals.

  9. Strategic Implications Of The Single Phase 3 Approval Paradigm 7/21/2026

    As FDA single-trial approvals gain traction, CNS developers need stronger early evidence. Learn how biomarkers, patient selection, and regulatory strategy can accelerate development.

  10. Unifying Research - HRPP Vs IRB And Participant Christine 7/21/2026

    HRPPs and IRBs play different but connected roles in protecting research participants. Hear expert guidance, firsthand experiences, and questions that can help people make more informed decisions.